Harnessing science and technology for personalised medicine

EDITED: 18/05/2018 | PUBLISHED: 23/03/2018

Lord O’Shaughnessy spoke to a room of parliamentarians and other stakeholders at our event at the House of Commons on 2 May. The Minister praised the UK’s leading health system, universities and life sciences sector, but stressed that to realise the opportunities for more personalised medicine we need to bring the public with us.

Prof Sir Munir Pirmohamed (University of Liverpool / Royal Liverpool University Hospital) and Dr Adam Platt (AstraZeneca) reflected on Lord O’Shaughnessy’s speech and posed questions on affordability and cost effectiveness of personalised medicine, and whether guidelines such as GDPR will reassure citizens about use of their personal health data.

Minutes available here
News available here

Quotes from the day

“We need to strain every sinew to bring the public with us. It needs to not sound like a science experiment, it needs to sound like something that is going to save my mum, my child, and provide reassurance about the kind of information that the state will hold about people and more importantly the purpose to which it will be put, which is about saving and extending lives.”

Lord O'Shaughnessy
Parliamentary Under Secretary of State for Health

“Personalised medicine is such an exciting and fast paced area of healthcare. It was fantastic to see so many clinicians and parliamentarians come together to hear from the Health Minister Lord O’Shaughnessy and those in the field. The UK is in a unique position to harness these emerging care opportunities thanks to our universities and NHS, as we heard from the speakers. This is the beginning of the conversation on personalised medicine, and I look forward to supporting the sector and the APPG in continuing that conversation.”

Helen Whateley MP
Chair APPG on Personalised Medicine

“We do at AstraZeneca strongly believe the UK should lead the world in optimal healthcare delivery and having the best research capability and science. We believe this can be a reality alluding to what was just said if we can link UK health records to genomic data and other biomedical data this will make a massive difference in terms of drug discovery, development, assessment and new interventions.”

Dr Adam Platt
VP & Head of R&I Precision Medicine and Global Genomics Portfolio, AstraZeneca

“It is not a matter of precision medicine verse public health it is actually public health and personalised medicine – it is not a competition. These are both things we should be focusing on and I think as we move forward we should be thinking about personalised prevention as well.”

Prof Sir Munir Pirmohamed
David Weatherall Chair in Medicine at the University of Liverpool, and Consultant Physician at the Royal Liverpool University Hospital